|
|
Phase II Study of Combination Chemotherapy in Adolescents and Young Adults With Newly Diagnosed Acute Lymphoblastic Leukemia
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Related Publications Trial Contact Information Related Information Registry Information
Alternate Title
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
16 to 30
|
|
|
|
NCI
|
|
|
|
CALGB-10403 CALGB 10403, CALGB-10403, ECOG C10403, SWOG C10403, NCT00558519
|
|
|
Objectives - To describe the outcomes (i.e., complete response rate, event-free survival, disease-free survival, and overall survival) of adolescents and young
adults with newly diagnosed acute lymphoblastic leukemia (ALL) treated with a pediatric chemotherapy
regimen by adult hematologists/oncologists at multiple sites.
- To describe the toxicities observed in these patients.
- To compare the outcomes of patients treated on this protocol with
appropriate similar patients (by age and disease characteristics) treated by pediatric
oncologists on protocol COG-AALL0232.
- To evaluate the adherence of adult hematologists/oncologists and their patients to a
"pediatric" ALL treatment regimen and identify reasons for variances.
- To analyze and describe the outcomes of patients treated on this study
according to pretreatment characteristics such as age, gender, white blood cell
count, other hematologic parameters, blood chemistry, immunophenotype,
cytogenetics and molecular genetic characteristics, and treatment variables such as
treatment site (academic center or community), and protocol adherence.
- To analyze and describe the outcomes of patients treated on this study
according to baseline psychosocial characteristics, demographics, and family
support.
Entry Criteria Disease Characteristics:
- Newly diagnosed acute
lymphoblastic leukemia (ALL)
- B-precursor or T-precursor ALL
- No Burkitt type leukemia (FAB L3; SIg
positive; t(8;14) or variant)
- No known Ph+ ALL at time of diagnosis
- Enrollment on CALGB-C10001 (or its successor trial) for CALGB patients with Philadelphia-positive ALL take priority over enrollment on this protocol
- Patients enrolled on this study but are later found to meet the following criteria for Ph+ ALL eligibility
criteria for
protocol CALGB-C10001 (or its successor trial) are removed from this study and enrolled on CALGB-C10001 (or its successor study):
- BCR-ABL fusion transcript determined by FISH or RT-PCR
- t(9;22)(q34;q11) or variant determined by cytogenetics
- All CALGB patients are required to participate in CALGB-8461
- All SWOG patients are required to participate in SWOG-9007
Prior/Concurrent Therapy:
- No prior therapy for acute leukemia except emergency therapy (i.e., corticosteroids or
hydroxyurea) for blast cell crisis, superior vena cava syndrome, or renal failure due to leukemic infiltration of the kidneys
- Single-dose intrathecal cytarabine is allowed prior to registration for patient
convenience provided systemic chemotherapy begins within 72 hours of intrathecal therapy
- Prior steroid therapy allowed
Patient Characteristics:
- ECOG performance status 0-2
- No Down syndrome
Expected Enrollment 300Outcomes Primary Outcome(s)Complete response rate Event-free survival Disease-free survival Overall survival Toxicity Outcomes of adolescent and young
adult patients treated on this study compared with those of patients treated per COG-AALL0232 Adherence of adult hematologists/oncologists and their patients to a
"pediatric" acute lymphoblastic leukemia treatment regimen and identification of reasons for variances Outcomes of patients treated on this study
according to pretreatment characteristics such as age, gender, white blood cell
count, other hematologic parameters, blood chemistry, immunophenotype,
cytogenetics and molecular genetic characteristics Outcomes of patients treated on this study
according to treatment variables such as
treatment site (academic center or community), and protocol adherence Analysis and description of the outcomes of patients treated on this study
according to baseline psychosocial characteristics, demographics, and family
support
Outline This is a multicenter study. - Remission induction therapy: Patients receive intrathecal (IT) cytarabine on day 1; vincristine IV on days 1, 8, 15, and 22; dexamethasone IV or orally twice daily on days 1-14; daunorubicin hydrochloride IV on days 1, 8, 15, and 22; pegaspargase IV or intramuscularly (IM) on day 4 or 5 or 6; and IT methotrexate on days 8 and 29*. Patients undergo bone marrow aspirate (BMA) and biopsy on day 29 to assess induction response and minimal residual disease status. Patients with M1 marrow (< 1% lymphoblasts) proceed to remission consolidation therapy. Patients with M2 marrow (> 5% but < 25% lymphoblasts) proceed to extended remission induction therapy. Patients with M3 marrow are removed from protocol therapy.
[Note: *Patients with CNS3 disease also receive IT methotrexate on days 15 and 22.]
- Extended remission induction therapy: Patients receive dexamethasone IV or orally twice daily on days 1-14; vincristine IV on days 1 and 8; pegaspargase IM or IV on day 4 or 5 or 6; and daunorubicin hydrochloride IV on day 1. Patients undergo BMA and biopsy on day 15. Patients with M1 marrow proceed to remission consolidation therapy. Patients with M2 or M3 bone marrow are removed from protocol therapy.
- Remission consolidation therapy: Patients receive cyclophosphamide IV on days 1 and 29; cytarabine IV or subcutaneously (SC) on days 1-4, 8-11, 29-32, and 36-39; oral mercaptopurine on days 1-14 and 29-42; vincristine IV on days 15, 22, 43, and 50; pegaspargase IM or IV on days 15 and 43; and IT methotrexate on days 1, 8, 15*, and 22*. Once blood counts recover, patients proceed to interim maintenance therapy.
[Note: *Patients with CNS3 disease do not receive IT methotrexate on days 15 and 22.]
- Interim maintenance therapy: Patients receive vincristine IV and methotrexate (Capizzi methotrexate) IV on days 1, 11, 21, 31, and 41, pegaspargase IM or IV on days 2 and 22, and IT methotrexate on days 1 and 31. Once blood counts recover (ANC ≥ 750/mm3 and platelet count ≥ 75,000/mm3), patients proceed to delayed intensification therapy.
- Delayed intensification therapy: Patients receive vincristine IV on days 1, 8, 15, 43, and 50; dexamethasone IV or orally twice daily on days 1-7 and 15-21; doxorubicin hydrochloride IV on days 1, 8, and 15; pegaspargase IM or IV on day 4 or 5 or 6 AND day 43; cyclophosphamide IV on day 29; cytarabine IV or SC on days 29-32 and 36-39; oral thioguanine on days 29-42; and IT methotrexate on days 1, 29, and 36. Once blood counts recover, patients proceed to maintenance therapy.
- Maintenance chemotherapy: Patients receive vincristine IV on days 1, 29, and 57; dexamethasone IV or orally twice daily on days 1-5, 29-33, and 57-61; mercaptopurine orally on days 1-84; IT methotrexate on day 1*; and oral methotrexate on days 8, 15, 22, 29**, 36, 43, 50,
57, 64, 71, and 78.
Treatment repeats every 12 weeks for 2 years from the start of interim maintenance (for female patients) or 3 years from the start of interim maintenance (for male patients). [Note: *IT methotrexate is also given on day 29 of the first 4 courses of maintenance therapy.] [Note: **Oral methotrexate is held on day 29 of the first 4 courses of maintenance therapy (when IT methotrexate is given).]
- Radiotherapy: During the first course of maintenance therapy, patients with
testicular disease undergo concurrent radiotherapy to the testes 5 days a week for 2.5 weeks (total dose 2400 cGy given in 12 daily fractions); patients with CNS3 disease undergo concurrent cranial radiotherapy 5 days a week for 2 weeks (total dose of 1800 cGy given in 10 daily fractions); and patients with T-cell ALL undergo concurrent cranial radiotherapy (total dose of 2400 cGy given in 10 daily fractions) 5 days a week for 2 weeks.
After completion of study treatment, patients are followed every 1-3 months for 3 years, and then every 6 months for 7 years. Related PublicationsBleyer A: Older adolescents and young adults with acute lymphoblastic leukemia (ALL) in the United States: from the lowest to highest death rate and number of deaths--more rationale for the CALBG-SWOG-ECOG C10403 trial based on COG AALL0232. [Abstract] J Clin Oncol 26 (Suppl 15): A-18034, 2008.
Trial Contact Information
Trial Lead Organizations Cancer and Leukemia Group B | | | Richard Larson, MD, Protocol chair | | Ph: 773-702-6783; 888-824-0200 |
| | John Grecula, MD, Protocol co-chair | | | |
Eastern Cooperative Oncology Group | | | Selina Luger, MD, Protocol chair | | | |
Southwest Oncology Group | | | Anjali Advani, MD, Protocol chair | | | | Trial Sites
|
|
|
|
U.S.A. |
|
Arizona |
|
|
Scottsdale |
|
| | | | | | | | Mayo Clinic Scottsdale |
| | Clinical Trials Office - All Mayo Clinic Locations | |
|
Delaware |
|
|
Lewes |
|
| | | Tunnell Cancer Center at Beebe Medical Center |
| | Clinical Trials Office - Tunnell Cancer Center | |
|
|
Newark |
|
| | CCOP - Christiana Care Health Services |
| | Clinical Trial Office - CCOP - Christiana Care Health Services | |
|
Florida |
|
|
Orlando |
|
| | | Florida Hospital Cancer Institute at Florida Hospital Orlando |
| | Clinical Trials Office - Florida Hospital Cancer Institute | |
|
Illinois |
|
|
Aurora |
|
| | | Rush-Copley Cancer Care Center |
| | Kendrith Rowland, MD | |
|
|
Bloomington |
|
| | St. Joseph Medical Center |
| | John Kugler, MD | |
|
|
Canton |
|
| | Graham Hospital |
| | John Kugler, MD | |
|
|
Carthage |
|
| | Memorial Hospital |
| | John Kugler, MD | |
|
|
Chicago |
|
| | Hematology and Oncology Associates |
| | Clinical Trails Office - Hematology and Oncology Associates | |
| | Robert H. Lurie Comprehensive Cancer Center at Northwestern University |
| | Clinical Trials Office - Robert H. Lurie Comprehensive Cancer Center at Northwestern University | |
| Email:
cancer@northwestern.edu |
| | University of Chicago Cancer Research Center |
| | Clinical Trials Office - University of Chicago Cancer Research Center | |
|
|
Eureka |
|
| | Eureka Community Hospital |
| | John Kugler, MD | |
|
|
Galesburg |
|
| | Galesburg Clinic, PC |
| | John Kugler, MD | |
| | Galesburg Cottage Hospital |
| | John Kugler, MD | |
|
|
Havana |
|
| | Mason District Hospital |
| | John Kugler, MD | |
|
|
Hopedale |
|
| | Hopedale Medical Complex |
| | John Kugler, MD | |
|
|
Joliet |
|
| | Joliet Oncology-Hematology Associates, Limited - West |
| | Kendrith Rowland, MD | |
| | Midwest Center for Hematology/Oncology |
| | Jessica Altman | |
|
|
Libertyville |
|
| | North Shore Oncology and Hematology Associates, Limited - Libertyville |
| | Jessica Altman | |
|
|
Macomb |
|
| | McDonough District Hospital |
| | John Kugler, MD | |
|
|
Naperville |
|
| | La Grange Oncology Associates - Geneva |
| | Jessica Altman | |
|
|
Normal |
|
| | BroMenn Regional Medical Center |
| | John Kugler, MD | |
| | Community Cancer Center |
| | John Kugler, MD | |
|
|
Ottawa |
|
| | Community Hospital of Ottawa |
| | John Kugler, MD | |
| | Oncology Hematology Associates of Central Illinois, PC - Ottawa |
| | John Kugler, MD | |
|
|
Pekin |
|
| | Cancer Treatment Center at Pekin Hospital |
| | John Kugler, MD | |
|
|
Peoria |
|
| | CCOP - Illinois Oncology Research Association |
| | John Kugler, MD | |
| | Methodist Medical Center of Illinois |
| | Clinical Trials Office - Methodist Medical Center of Illinois | |
| | Oncology Hematology Associates of Central Illinois, PC - Peoria |
| | John Kugler, MD | |
| | OSF St. Francis Medical Center |
| | John Kugler, MD | |
| | Proctor Hospital |
| | John Kugler, MD | |
|
|
Peru |
|
| | Illinois Valley Community Hospital |
| | John Kugler, MD | |
|
|
Princeton |
|
| | Perry Memorial Hospital |
| | John Kugler, MD | |
|
|
Skokie |
|
| | Hematology Oncology Associates - Skokie |
| | Jessica Altman | |
|
|
Spring Valley |
|
| | St. Margaret's Hospital |
| | John Kugler, MD | |
|
|
Urbana |
|
| | Carle Cancer Center at Carle Foundation Hospital |
| | Clinical Trials Office - Carle Cancer Center | |
| | CCOP - Carle Cancer Center |
| | Clinical Trials Office - CCOP - Carle Cancer Center | |
|
Indiana |
|
|
Beech Grove |
|
| | | St. Francis Hospital and Health Centers - Beech Grove Campus |
| | Howard Gross, MD | |
|
|
Fort Wayne |
|
| | Fort Wayne Medical Oncology and Hematology |
| | Sreenivasa Nattam, MD | Ph: | 260-484-8830 | | 800-852-2333 |
|
|
|
Michigan City |
|
| | Saint Anthony Memorial Health Centers |
| | Kendrith Rowland, MD | |
|
|
Richmond |
|
| | Reid Hospital & Health Care Services |
| | Howard Gross, MD | |
|
Iowa |
|
|
Ames |
|
| | | McFarland Clinic, PC |
| | Clinical Trials Office - McFarland Clinic, PC | |
|
|
Des Moines |
|
| | CCOP - Iowa Oncology Research Association |
| | Roscoe Morton, MD, FACP | |
| | John Stoddard Cancer Center at Iowa Lutheran Hospital |
| | Clinical Trials Office - John Stoddard Cancer Center at Iowa Lutheran Hospital | |
| | John Stoddard Cancer Center at Iowa Methodist Medical Center |
| | Clinical Trials Office - John Stoddard Cancer Center at Iowa Methodist Medical Center | |
| | Medical Oncology and Hematology Associates at John Stoddard Cancer Center |
| | Roscoe Morton, MD, FACP | |
| | Medical Oncology and Hematology Associates at Mercy Cancer Center |
| | Roscoe Morton, MD, FACP | |
| | Mercy Cancer Center at Mercy Medical Center - Des Moines |
| | Roscoe Morton, MD, FACP | |
| | Mercy Capitol Hospital |
| | Roscoe Morton, MD, FACP | |
|
|
Iowa City |
|
| | Holden Comprehensive Cancer Center at University of Iowa |
| | Cancer Information Service | |
|
|
Sioux City |
|
| | Mercy Medical Center - Sioux City |
| | Donald Wender, MD, PhD | |
| | Siouxland Hematology-Oncology Associates, LLP |
| | Donald Wender, MD, PhD | |
| | St. Luke's Regional Medical Center |
| | Donald Wender, MD, PhD | |
|
Kansas |
|
|
Chanute |
|
| | | Cancer Center of Kansas, PA - Chanute |
| | Shaker Dakhil, MD, FACP | |
|
|
Dodge City |
|
| | Cancer Center of Kansas, PA - Dodge City |
| | Shaker Dakhil, MD, FACP | |
|
|
El Dorado |
|
| | Cancer Center of Kansas, PA - El Dorado |
| | Shaker Dakhil, MD, FACP | |
|
|
Independence |
|
| | Cancer Center of Kansas-Independence |
| | Shaker Dakhil, MD, FACP | |
|
|
Kingman |
|
| | Cancer Center of Kansas, PA - Kingman |
| | Shaker Dakhil, MD, FACP | |
|
|
Liberal |
|
| | Southwest Medical Center |
| | Shaker Dakhil, MD, FACP | |
|
|
Newton |
|
| | Cancer Center of Kansas, PA - Newton |
| | Shaker Dakhil, MD, FACP | |
|
|
Parsons |
|
| | Cancer Center of Kansas, PA - Parsons |
| | Shaker Dakhil, MD, FACP | |
|
|
Pratt |
|
| | Cancer Center of Kansas, PA - Pratt |
| | Shaker Dakhil, MD, FACP | |
|
|
Salina |
|
| | Cancer Center of Kansas, PA - Salina |
| | Shaker Dakhil, MD, FACP | |
|
|
Topeka |
|
| | Cotton-O'Neil Cancer Center |
| | Clinical Trials Office - Cotton-O'Neil Cancer Center | |
|
|
Wellington |
|
| | Cancer Center of Kansas, PA - Wellington |
| | Shaker Dakhil, MD, FACP | |
|
|
Wichita |
|
| | Associates in Womens Health, PA - North Review |
| | Shaker Dakhil, MD, FACP | |
| | Cancer Center of Kansas, PA - Wichita |
| | Shaker Dakhil, MD, FACP | |
| | Cancer Center of Kansas, PA - Medical Arts Tower |
| | Shaker Dakhil, MD, FACP | |
| | CCOP - Wichita |
| | Shaker Dakhil, MD, FACP | |
| | Via Christi Cancer Center at Via Christi Regional Medical Center |
| | Shaker Dakhil, MD, FACP | |
| | Wesley Medical Center |
| | Shaker Dakhil, MD, FACP | |
|
|
Winfield |
|
| | Cancer Center of Kansas, PA - Winfield |
| | Shaker Dakhil, MD, FACP | |
|
Maryland |
|
|
Baltimore |
|
| | | Greenebaum Cancer Center at University of Maryland Medical Center |
| | Clinical Trials Office - Greenebaum Cancer Center at University of Maryladn Medical Center | |
|
|
Elkton MD |
|
| | Union Hospital Cancer Program at Union Hospital |
| | Stephen Grubbs, MD | |
|
Minnesota |
|
|
Rochester |
|
| | | Mayo Clinic Cancer Center |
| | Clinical Trials Office - All Mayo Clinic Locations | |
|
Missouri |
|
|
Columbia |
|
| | | Ellis Fischel Cancer Center at University of Missouri - Columbia |
| | Clinical Trial Office - Ellis Fischel Cancer Center | |
|
|
Saint Louis |
|
| | Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis |
| | Ravi Vij, MD | Ph: | 314-747-7222 | | 800-600-3606 |
|
|
Montana |
|
|
Billings |
|
| | | Billings Clinic - Downtown |
| | Clinical Trials Office - Billings Clinic - Downtown | |
| Email:
research@billingsclinic.org |
| | CCOP - Montana Cancer Consortium |
| | Benjamin Marchello, MD | Ph: | 406-259-2245 | | 800-361-3239 |
|
| | Hematology-Oncology Centers of the Northern Rockies - Billings |
| | Benjamin Marchello, MD | Ph: | 406-238-6290 | | 800-648-6274 |
|
| | Northern Rockies Radiation Oncology Center |
| | Benjamin Marchello, MD | Ph: | 406-248-2212 | | 800-358-8818 |
|
| | St. Vincent Healthcare Cancer Care Services |
| | Benjamin Marchello, MD | |
|
|
Bozeman |
|
| | Bozeman Deaconess Cancer Center |
| | Benjamin Marchello, MD | |
|
|
Butte |
|
| | St. James Healthcare Cancer Care |
| | Benjamin Marchello, MD | |
|
|
Great Falls |
|
| | Benjamin Marchello, MD | |
| | Great Falls Clinic - Main Facility |
| | Benjamin Marchello, MD | Ph: | 406-454-2171 | | 800-421-1649 |
|
|
|
Helena |
|
| | St. Peter's Hospital |
| | Benjamin Marchello, MD | |
|
|
Kalispell |
|
| | Glacier Oncology, PLLC |
| | Benjamin Marchello, MD | |
| | Kalispell Medical Oncology at KRMC |
| | Benjamin Marchello, MD | |
| | Kalispell Regional Medical Center |
| | Benjamin Marchello, MD | |
|
|
Missoula |
|
| | Community Medical Center |
| | Benjamin Marchello, MD | |
| | Guardian Oncology and Center for Wellness |
| | Benjamin Marchello, MD | |
| | Montana Cancer Center at St. Patrick Hospital and Health Sciences Center |
| | Clinical Trials Office - Montana Cancer Center at St. Patrick Hospital and Health Sciences Center | |
| | Montana Cancer Specialists at Montana Cancer Center |
| | Clinical Trials Office - Montana Cancer Specialists at Montana Cancer Center | |
|
New Jersey |
|
|
Voorhees |
|
| | | Cancer Institute of New Jersey at Cooper - Voorhees |
| | Clinical Trials Office - Cancer Institute of New Jersey at Cooper University Hospital - Voorhees | |
|
New York |
|
|
Buffalo |
|
| | | Roswell Park Cancer Institute |
| | Clinical Trials Office - Roswell Park Cancer Institute | |
|
|
Lake Success |
|
| | Long Island Radiation Therapy - Lake Success |
| | Jonathan Kolitz, MD | |
|
|
Manhasset |
|
| | CCOP - North Shore University Hospital |
| | Jonathan Kolitz, MD | |
| | Don Monti Comprehensive Cancer Center at North Shore University Hospital |
| | Clinical Trials Office - Don Monti Comprehensive Cancer Center at North Shore University Hospital | |
|
|
New Hyde Park |
|
| | Long Island Jewish Medical Center |
| | Jonathan Kolitz, MD | |
|
|
New York |
|
| | New York Weill Cornell Cancer Center at Cornell University |
| | Clinical Trials Office - New York Weill Cornell Cancer Center at Cornell University | |
|
North Carolina |
|
|
Chapel Hill |
|
| | | Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill |
| | Clinical Trials Office - Lineberger Comprehensive Cancer Center | Ph: | 877-668-0683; 919-966-4432 | | |
|
|
|
Goldsboro |
|
| | Wayne Memorial Hospital, Incorporated |
| | James Atkins, MD | |
|
|
Winston-Salem |
|
| | Wake Forest University Comprehensive Cancer Center |
| | Clinical Trials Office - Wake Forest University Comprehensive Cancer Center | |
|
Ohio |
|
|
Canton |
|
| | | Aultman Cancer Center at Aultman Hospital |
| | Clinical Trials Office - Aultman Cancer Center at Aultman Hospital | |
|
|
Cleveland |
|
| | Cleveland Clinic Taussig Cancer Center |
| | Clinical Trials Office - Cleveland Clinic Taussig Cancer Center | |
|
|
Columbus |
|
| | Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center |
| | Clinical Trials Office - OSU Comprehensive Cancer Center | |
| Email:
osu@emergingmed.com |
|
|
Dayton |
|
| | CCOP - Dayton |
| | Howard Gross, MD | |
| | David L. Rike Cancer Center at Miami Valley Hospital |
| | Clinical Trials Office - David L. Rike Cancer Center at Miami Valley Hospital | |
| | Good Samaritan Hospital |
| | Howard Gross, MD | |
| | Grandview Hospital |
| | Howard Gross, MD | |
| | Samaritan North Cancer Care Center |
| | Howard Gross, MD | Ph: | 937-279-5800 | | 800-616-6784 |
|
| | Veterans Affairs Medical Center - Dayton |
| | Howard Gross, MD | |
|
|
Findlay |
|
| | Blanchard Valley Medical Associates |
| | Howard Gross, MD | |
|
|
Franklin |
|
| | Middletown Regional Hospital |
| | Howard Gross, MD | |
|
|
Kettering |
|
| | Charles F. Kettering Memorial Hospital |
| | Clinical Trials Office - Charles F. Kettering Memorial Hospital | Ph: | 937-298-3399 ext. 57556 | | |
|
|
|
Troy |
|
| | UVMC Cancer Care Center at Upper Valley Medical Center |
| | Clinical Trials Office - UVMC Cancer Care Center at Upper Valley Medical Center | |
|
|
Wilmington |
|
| | Clinton Memorial Hospital |
| | Howard Gross, MD | |
|
|
Xenia |
|
| | Ruth G. McMillan Cancer Center at Greene Memorial Hospital |
| | Howard Gross, MD | |
|
Pennsylvania |
|
|
Philadelphia |
|
| | | Abramson Cancer Center of the University of Pennsylvania |
| | Clinical Trials Office - Abramson Cancer Center of the University of Pennsylvania | |
|
South Carolina |
|
|
Charleston |
|
| | | Hollings Cancer Center at Medical University of South Carolina |
| | Clinical Trials Office - Hollings Cancer Center at Medical University of South Carolina | |
|
Vermont |
|
|
Berlin |
|
| | | Mountainview Medical |
| | Barbara Grant, MD | |
|
|
Burlington |
|
| | Fletcher Allen Health Care - University Health Center Campus |
| | Clinical Trials Office - Fletcher Allen Health Care | |
|
Virginia |
|
|
Richmond |
|
| | | Virginia Commonwealth University Massey Cancer Center |
| | Clinical Trials Office -Virginia Commonwealth University Massey Cancer Center | |
|
Washington |
|
|
Bellingham |
|
| | | St. Joseph Cancer Center |
| | Saul Rivkin, MD | |
|
|
Bremerton |
|
| | Olympic Hematology and Oncology |
| | Saul Rivkin, MD | |
|
|
Kennewick |
|
| | Columbia Basin Hematology |
| | Saul Rivkin, MD | |
|
|
Seattle |
|
| | Fred Hutchinson Cancer Research Center |
| | Saul Rivkin, MD | |
| | Group Health Central Hospital |
| | Clinical Trials Office - Group Health Central Hospital | |
| | Harborview Medical Center |
| | Saul Rivkin, MD | |
| | Minor and James Medical, PLLC |
| | Saul Rivkin, MD | |
| | Polyclinic First Hill |
| | Saul Rivkin, MD | |
| | Swedish Cancer Institute at Swedish Medical Center - First Hill Campus |
| | Saul Rivkin, MD | |
| | University Cancer Center at University of Washington Medical Center |
| | Clinical Trials Office - University Cancer Center at University of Washington Medical Center | |
|
|
Spokane |
|
| | Cancer Care Northwest - Spokane South |
| | Clinical Trials Office - Cancer Care Northwest - Spokane South | |
|
Wyoming |
|
|
Sheridan |
|
| | | Welch Cancer Center at Sheridan Memorial Hospital |
| | Benjamin Marchello, MD | |
|
Related Information PDQ® clinical trial CALGB-C10001 PDQ® clinical trial COG-AALL0232 PDQ® clinical trial CALGB-8461
Registry Information | | Official Title | | An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL) | | Trial Start Date | | 2007-10-15 | | Trial Completion Date | | 2012-09-18 (estimated) | | Registered in ClinicalTrials.gov | | NCT00558519 | | Date Submitted to PDQ | | 2007-10-23 | | Information Last Verified | | 2008-10-20 | | NCI Grant/Contract Number | | CA31946 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|